iTeos Therapeutics Inc. (ITOS)
6.32
-0.38 (-5.74%)
At close: Mar 28, 2025, 3:59 PM
6.48
2.53%
After-hours: Mar 28, 2025, 05:14 PM EDT
Company Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients.
The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
iTeos Therapeutics Inc.

Country | United States |
IPO Date | Jul 24, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 173 |
CEO | Dr. Michel Detheux Ph.D. |
Contact Details
Address: 321 Arsenal Street Cambridge, Massachusetts United States | |
Website | https://www.iteostherapeutics.com |
Stock Details
Ticker Symbol | ITOS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001808865 |
CUSIP Number | 46565G104 |
ISIN Number | US46565G1040 |
Employer ID | 00-0000000 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Michel Detheux Ph.D. | President, Chief Executive Officer & Director |
Matthew Gall | Chief Financial Officer |
Matthew A. Call M.B.A. | Chief Operating Officer |
Adi Osovsky | Executive Vice President of Legal |
Dr. David Feltquate M.D., Ph.D. | Chief Medical Officer |
Dr. Yvonne McGrath Ph.D. | Chief Scientific Officer |
Philippe Brantegem | Executive Vice President of Human Resources |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 11, 2025 | 4 | Filing |
Mar 11, 2025 | 4 | Filing |
Mar 11, 2025 | 4 | Filing |
Mar 11, 2025 | 4 | Filing |
Mar 05, 2025 | S-8 | Filing |
Mar 05, 2025 | 10-K | Annual Report |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Jan 13, 2025 | 8-K | Current Report |
Dec 06, 2024 | 4 | Filing |
Nov 21, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |